All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
On July 8, 2024, the European Medicines Agency (EMA) granted Orphan Drug Designation to SLS009, a highly selective CDK9 inhibitor, for the treatment of patients with acute myeloid leukemia (AML). SLS009 was previously granted Orphan Drug Designation and Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of AML.
SLS009 is currently being investigated in combination with azacitidine and venetoclax in an open-label, single arm phase IIa clinical trial (NCT04588922), to evaluate its safety, tolerability, and efficacy, at two dose levels, 45 and 60 mg in patients with relapsed/refractory AML, including those with ASXL1 mutations.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox